Our Programs

Tiburio is advancing a pipeline of clinic ready assets.

Tiburio is advancing a pipeline of clinic ready assets.

Tiburio’s clinical stage pipeline is based on dopamine-somatostatin chimeric molecules for the treatment of severe endocrine disorders. Dopamine-somatostatin chimeric compounds have evolved as a therapeutic drug class with the potential to have broad application across various endocrine diseases [1]. Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that result in enhanced activity, offering new potential for a variety of diseases with unmet need [2,3].

CompoundPreclinicalPhase 1Phase 2Phase 3
TBR-760

For treatment of NFPA.

Preclinical
Phase 1
Phase 2
Phase 3
TBR-065

For treatment of rare endocrine disorders.

Preclinical
Phase 1
Phase 2
Phase 3
References:

[1] Culler MD. (2011). “Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors.” Horm. Metab. Res.; 43: 854- 857.

[2] Tiburio, unpublished data on file.

[3] Halem H. (2016). A Novel Somatostatin-­Dopamine Chimeric Compound Induces Dose‐Related Suppression of GHRH-­Stimulated Growth Hormone Secretion and Increases Insulin Sensitivity in Normal Rats. Poster session presented at the ENDO 2016 meeting, San Francisco, CA.